8-K: bioAffinity Technologies Presents CyPath Lung Data

bioAffinity Technologies announced presentations at the NAVREF 2026 Annual Conference showcasing its noninvasive lung cancer diagnostic, CyPath Lung, in clinical practice and veteran-focused research.

Summary

• bioAffinity Technologies is presenting two posters at the 2026 NAVREF Annual Conference (September 27-30, 2026) in Arlington, Virginia.
• The presentations focus on the CyPath Lung noninvasive diagnostic for lung cancer, highlighting its use in clinical practice and ongoing research in veteran and military populations.
• The company's new distribution partner, AvMEDICAL, will also be present to discuss commercial momentum and healthcare benefits.
• The NAVREF conference is the first joint engagement with the federal healthcare market for bioAffinity Technologies and AvMEDICAL.
• Lung cancer is a significant challenge for veterans, with approximately 7,700 diagnosed annually.
• CyPath Lung aims to provide real-time information about lung nodules identified through imaging.
• Poster 1, 'CyPath Lung in Practice,' details three clinical cases where the test aided in diagnosis, guided discussions, and prevented unnecessary invasive procedures.
• Poster 2, 'Longitudinal Study on Detection of Early-Stage Lung Cancer in Sputum,' describes the FlowPath Lung study, a 2,000-patient longitudinal study in veteran and military populations using the CyPath Lung test.
• The FlowPath Lung study utilizes at-home sputum collection and has previously reported performance metrics of 92% sensitivity, 87% specificity, and 99% negative predictive value for nodules of 20 mm or less.
• An economic analysis from 2024 suggested potential savings of thousands of dollars per person and hundreds of millions overall in healthcare costs associated with lung cancer screening and diagnosis using bioAffinity's test.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, highlighting progress in clinical application and research for a key diagnostic tool, with potential for significant cost savings.

Positives

• Presentation of positive clinical and veteran-focused data on CyPath Lung at a relevant conference.
• Highlighting the beneficial role of CyPath Lung in veteran lung cancer care.
• Demonstration of CyPath Lung's ability to accelerate diagnosis, guide clinical discussions, and prevent unnecessary invasive procedures in complex cases.
• Ongoing 2,000-patient longitudinal study (FlowPath Lung) evaluating CyPath Lung in veteran and military populations.
• CyPath Lung's at-home sputum collection feature eliminates the need for patient travel to VA facilities.
• Previously reported performance metrics for CyPath Lung in nodules of 20 mm or less: 92% sensitivity, 87% specificity, and 99% negative predictive value.
• Potential for significant healthcare cost savings, estimated in the thousands per person and hundreds of millions overall, based on a 2024 economic analysis.

Negatives

• The reported performance metrics (92% sensitivity, 87% specificity, 99% NPV) may not be indicative of performance in broader populations or different clinical settings.
• The economic analysis projections for cost savings are based on third-party analyses using assumptions that may not reflect actual clinical outcomes, reimbursement rates, utilization patterns, or healthcare system dynamics.
• The FlowPath Lung clinical study is currently enrolling patients, indicating it is not yet completed.

Risks

• The potential for actual savings to differ materially from projected savings due to variations in clinical outcomes, reimbursement, utilization, and healthcare system dynamics.
• Uncertainties regarding the actual economic impact of the diagnostic technology in clinical practice.
• Changes in healthcare reimbursement policies and payor coverage decisions.
• Competition and technological changes in the biotechnology and diagnostics industries.
• The company's need for additional financing.
• Risks related to government contracts and the federal procurement process.
• The forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations.

Future Outlook

The company is presenting data on its CyPath Lung diagnostic at the NAVREF conference, highlighting its clinical application and ongoing research in veteran populations. The company also notes potential significant cost savings associated with its technology. However, actual savings may differ materially from projections.

Management Comments

• "At the NAVREF conference we will share how CyPath Lung may benefit veterans by providing real-time information about lung nodules discovered by imaging."
• "The VA has made substantial progress in expanding lung cancer screening for veterans, which means a significant increase in the number of lung nodules that require careful evaluation."

Industry Context

StockSavvy.ai notes that the focus on veteran populations and the potential for cost savings aligns with broader trends in healthcare technology adoption, particularly for diagnostics that offer noninvasive methods and improve efficiency in managing chronic diseases like lung cancer.

Comparison to Industry Standards

• The reported performance metrics (92% sensitivity, 87% specificity, 99% NPV) for CyPath Lung in nodules of 20 mm or less are presented as benchmarks for its efficacy in specific patient subsets.
• The economic analysis suggesting significant cost savings per patient and overall for the healthcare system positions CyPath Lung as a potentially cost-effective solution compared to traditional diagnostic pathways, though specific comparable cost-saving figures from other diagnostic technologies are not detailed in this filing.

Stakeholder Impact

• Shareholders: Potential positive impact from the advancement and potential market penetration of CyPath Lung, especially within the veteran healthcare system.
• Veterans and Military Populations: Direct benefit from improved early detection and monitoring of lung cancer through a noninvasive test, potentially reducing the need for invasive procedures and improving diagnostic accuracy.
• Healthcare Providers: Access to a diagnostic tool that can aid in diagnosis, guide clinical discussions, and potentially reduce healthcare costs.
• VA and Federal Healthcare System: Potential for significant cost savings in lung cancer screening and diagnosis.

Next Steps

• Presenting two posters at the 2026 NAVREF Annual Conference.
• Engaging with the federal healthcare market through AvMEDICAL.
• Continuing enrollment in the FlowPath Lung study.
• Discussing potential healthcare benefits and commercial momentum of CyPath Lung.

Key Dates

Recommendation

The filing presents positive developments regarding clinical data and potential cost savings for CyPath Lung, particularly within the veteran population. However, the results are from ongoing studies and analyses, and the company acknowledges that actual outcomes may differ. The company also faces ongoing risks related to financing, competition, and regulatory approvals. Therefore, a 'hold' recommendation is appropriate pending further clinical validation and commercial progress.

Keywords

lung cancer diagnostic, noninvasive, CyPath Lung, veteran healthcare, flow cytometry, AI, sputum collection, pulmonary nodules